Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Bullboard Posts
Post by Righttothetopon Mar 30, 2020 9:06am
194 Views
Post# 30859265

Facts

Facts
Facts:

Year end revenues > $125mil
Year end EBIT $25mil
Australian GMP granted
Shipments to Australia occurred
$9mil from Hexo being litigated (and if you think they won't get anything, you're dreaming)


The financials are strong and will get stronger.  They are executing their global plan to perfection and only need EU GMP to open the German market (with already strong partner in pocket).

Like most companies in the space, the Canadian rollout hampered them a bit and COVID will put a damper on things, but vices always sell (even in down times, like the article posted earlier suggests), so do you think more or less people are going to hit the anti-anxiety CBD oil?

Boggles my mind why the price is heading lower today, if anything it should hold steady and maybe even head a bit higher to the next plateau.

Bullboard Posts